New Research Poster Presentation 3.18: Safety and Efficacy of ABT-089, a Novel Alpha-4-Beta-2 Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of Children with ADHD

Thursday, October 29, 2009 12:30 PM

Laura M. Gault, M.D., Ph.D., Abbott Laboratories, Abbott Park, IL

George Apostol, M.D., M.S., Abbott Laboratories, Glenview, IL

Timothy E. Wilens, M.D., Massachusetts General Hospital, Boston, MA

Christopher J. Kratochvil, M.D., University of Nebraska Medical Center, Omaha, NE

Weining Z. Robieson, Ph.D., Abbott Laboratories, Abbott Park, IL

Coleen Hall, M.B.A., M.S., Abbott Laboratories, Abbott Park, IL

Walid M. Abi-Saab, M.D., Novartis Pharmaceutical Corporation, Basel, Switzerland

Mario Saltarelli, M.D., Ph.D., Abbott Laboratories, Abbott Park, IL

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 3.18 Safety and Efficacy of ABT-089, a Novel Alpha-4-Beta-2 Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of Children with ADHD